Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eryaspase with Chemotherapy in 2nd-Line Pancreatic Adenocarcinoma
NCT03665441Phase 3Completed
- Sponsor
- PHAXIAM Therapeutics
- Start
- Sep 2018
- Primary completion
- Aug 2021
- Modality
- Replacement Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of eryaspase in pancreatic adenocarcinoma (PDAC), sponsored by PHAXIAM Therapeutics. Started Sep 2018; status: completed.
02
Drugs
eryaspase
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03665441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03665441.